Enumeral Biomedical Holdings Inc fka ENUMQ

[undtrdr]

In terms of our current cash 'crunch', I have no worry whatsoever that something else is very near ....it may seem like the 11th hour to some and I too appreciate their candid verbiage in the Q (might even help to fill my bids) ;), but I have full confidence knowing Dr. Tinkelenberg's background. In addition to his PhD/Life Sciences Research, over the last decade or so he has actually been primarily involved with Healthcare Investment Banking/Mergers/Acquisitions

I know I am repeating myself and that you know this RK but for new visitors I submit that Dr. Tinkelenberg is a master of negotiations:

Quote:
Dr. Arthur H. Tinkelenberg, also known as Art, Ph.D., is a Co-Founder of Enumeral Biomedical Holdings, Inc. and has been its President and Chief Executive Officer since July 31, 2014. Prior to co-founding and leading Enumeral, Dr. Tinkelenberg was a Venture Partner of Ascent BioMedical Ventures (ABV). At Ascent Biomedical Ventures, he was responsible for originating and managing numerous biotechnology and medical device company investments from 2003 to 2009. Prior to joining ABV, he worked in the Healthcare Investment Banking and Mergers and Acquisitions Groups at Robertson Stephens from January 2001 to July 2002, where he advised clients on strategic and financing alternatives and participated in over $250 million in public, private, and merger transactions for biotechnology, medical device, and diagnostics companies. Dr. Tinkelenberg served as President and Chief Executive Officer of Enumeral Biomedical Corporation since 2010. He has broad experience in the business and finance of healthcare enterprises and basic life sciences research. Prior to industry, he conducted research in lipid metabolism, genomics, biochemistry, and cell biology as a Research Scientist at Columbia University from 1996 to 2000. Dr. Tinkelenberg has been a Director of Enumeral Biomedical Holdings, Inc. since July 31, 2014. He serves as a Director of Crosstrees Medical, Inc. and Ouroboros. He is a Board Observer for Azevan Pharmaceuticals, Metronome Therapeutics, and Vivios Pharmaceuticals. He served as a Director of Enumeral Biomedical Corporation since 2010. He served as a Director of Xlumena, Inc. He is a published author and inventor on a number of patents from projects initiated by him during his tenure in academic research. Dr. Tinkelenberg earned his Ph.D. degree in Molecular Genetics from The Rockefeller University where he studied cell growth regulation and signal transduction as a Rockefeller and National Science Foundation Fellow and earned his BA degree in Biology, with honors, from Grinnell College.


IMO, Pieris got a bargain on the one hand to get our "licensing & royalty MACHINE" rolling, (using your quote, I love that one), but in the other is the NON-exclusive component that leaves the door wide open for potential similar deals.

...and especially too with TIM-3 still in the offing where we evidently should really excel in this new age of research.

I don't find it unusual at all that he waits to play his cards for the best outcome in the longer run for the company .. I think he could pull the trigger on more non-dilutive financing any time he wants and thus is courting all the options fastidiously.

All in my own opinion which was substantiated for me the day I watched this presentation ...note the second last answer he gives in the Q&A is never more pertinent than now and bodes very well for Enumeral's innovations with BP suitors http://noble.mediasite.com/mediasite/Play/5355702bbd66458b989daa6759bc54071d?catalog=3a734bfc-b7b0-4496-95ea-5193c0db8116